Women with germline inactivating mutations in the BRCA1 and BRCA2 genes are at significantly elevated risk of breast and ovarian cancer. Clinical genetic testing for mutations in these genes has become an important part of clinical practice because of the surgical prevention and targeted treatment benefits associated with knowledge of the presence of a cancer predisposing mutation. However, this process is often complicated by the detection of Variants of Uncertain Significance (VUS), which are predominantly missense mutations with an unknown influence on protein function and unknown association with cancer risk. The lack of information about these VUS means that individuals found to carry these variants cannot benefit from enhanced risk assessment or make informed decisions about surgical prevention or tailored treatment options such as platinum and PARP inhibitor therapy. Here we propose to determine the cancer relevance of VUS found throughout the BRCA1 and BRCA2 genes by developing a comprehensive model incorporating new genetic and functional approaches for VUS classification. However, because BRCA1 and BRCA2 are large proteins, with several established distinct functions that may or may not have a role in cancer development, the contribution of the different functions to tumor suppression and cancer risk must be determined before assays can be applied to VUS classification. Thus, in Aim1 we will perform a comprehensive functional analysis of BRCA1 variants to determine which molecular functions contribute to tumor suppression and in Aim 2 we will perform a comprehensive functional analysis of BRCA2 variants to determine which molecular functions influence the risk of cancer. Specifically, we will evaluate the influence of known pathogenic and non- pathogenic variants on defined functions of BRCA1 and BRCA2 and then extend our analyses to VUS using the assays found to be associated with cancer risk.
In Aim 3 we propose to extend the multifactorial model for classification of BRCA1 and BRCA2 VUS. Here we will develop new methods allowing incorporation of personal and family histories of VUS probands into an established predictive model. We will apply the model to classification of candidate moderate risk VUS, and most importantly, we will develop a Bayesian mixture model that integrates quantitative functional assay data with genetic data for the purposes of VUS classification.

Public Health Relevance

These efforts will result in determination of which of the known functions of BRCA1 and BRCA2 are associated with cancer risk and will lead to development of functional assays for characterization of VUS. It will then be possible to combine these assays with results from genetic studies to formally classify the cancer relevance of many VUS in the BRCA1 and BRCA2 genes. Overall, the study will ensure improved selection of VUS carriers who can benefit from various forms of intervention to prevent and/or treat breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA116167-07
Application #
8726295
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Mietz, Judy
Project Start
2013-09-01
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
7
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Schmidt, Marjanka K; Hogervorst, Frans; van Hien, Richard et al. (2016) Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. J Clin Oncol 34:2750-60
Petridis, Christos; Brook, Mark N; Shah, Vandna et al. (2016) Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Res 18:22
Hu, Chunling; Hart, Steven N; Bamlet, William R et al. (2016) Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients. Cancer Epidemiol Biomarkers Prev 25:207-11
Muranen, Taru A; Blomqvist, Carl; Dörk, Thilo et al. (2016) Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium. Breast Cancer Res 18:98
Maxwell, Kara N; Hart, Steven N; Vijai, Joseph et al. (2016) Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. Am J Hum Genet 98:801-17
Walsh, Michael F; Nathanson, Katherine L; Couch, Fergus J et al. (2016) Genomic Biomarkers for Breast Cancer Risk. Adv Exp Med Biol 882:1-32
Hamdi, Yosr; Soucy, Penny; Kuchenbaeker, Karoline B et al. (2016) Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat :
(2016) Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res 18:64
(2016) Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat Genet 48:374-86
(2016) BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst 108:

Showing the most recent 10 out of 67 publications